Breast cancer is the most common malignant tumor affecting women. Adjuvant systemic
therapies have been shown to have a significant impact on reducing the risk for breast …

Background: Chronic treatment sequelae may substantially reduce the long-term quality of
life in breast cancer survivors. Methods: We report a comprehensive Web-based survey on …

The decision to receive chemotherapy or chemohormonal therapy involves careful
consideration of both the potential benefits and possible risks of therapy. There are …

Breast cancer is a chronic and heterogeneous disease that may recur many years after
initial diagnosis and treatment. 1 This has important implications for the practicing …

Women with primary invasive breast cancer receive both local and systemic treatment.
Surgery and radiation therapy are local treatments given to reduce the risk of recurrent …

Adjuvant systemic therapy along with screening has been key to the observed
improvements in disease-free and overall survival (DFS/OS) in breast cancer. Improvements …

The prognosis of patients with early stage breast cancer has greatly improved in the past
three decades. Following the first adjuvant endocrine therapy and chemotherapy trials …

Introduction: Recent improvements in the survival of hormone-responsive breast cancer are
strongly associated with therapeutic advances, particularly with the uptake of adjuvant …

Breast cancer is the most common cancer diagnosed in women in the United States. More
than 180,000 new cases of invasive breast cancer were projected in 2000, with more than …

Breast irradiation, adjuvant chemotherapy, and tamoxifen are associated with an increased
risk of second cancers that may manifest decades after treatment. Although very small, it is …